Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2018-12-26 Major Shareholding Noti…
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including reasons for changes such as director resignations and share count adjustments. This falls under the category of Major Shareholding Notification.
2018-12-26 Korean
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure ('자율공시') regarding the acquisition of a patent ('특허권 취득') by LegoChem Biosciences. It details the patent name, its technical content, the patent holder, and the company's future utilization plans. Since this is a specific regulatory announcement regarding a corporate event (patent acquisition) that does not fall into financial reporting, M&A, or other specific categories, it is classified as a general regulatory filing.
2018-12-19 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the closure of the shareholder register for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of a corporate action related to shareholder rights. Given the nature of the announcement and its brevity, it falls under the category of general regulatory filings.
2018-12-10 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea used to disclose significant changes in share ownership (crossing thresholds). It details the reporting entity (Atinum Investment), the issuer (LegoChem Biosciences), and specific transaction history (disposals/sales). This falls under the 'Major Shareholding Notification' category.
2018-12-10 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details the acquisition of shares by Quad Investment Management Corp in LegoChem Biosciences. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels.
2018-11-28 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees/executives, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding share-based compensation and capital changes falls under the category of share issues or capital changes.
2018-11-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.